BioPharmSignal logoBioPharmSignal

Biotech News

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

Exagen (XGN)ExagenEarnings

CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026, before the market opens on Monday, May 11, 2026. John Aballi, President and Chief Executive

Open original release

Related news

XGNExagen2026-05-11 12:00 EST

Exagen Inc. Reports First Quarter 2026 Results

SABSSAB Biotherapeutics2026-05-05 12:30 EST

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

IMVTImmunovant2026-07-23 20:05 EST

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

HCWBHCW Biologics2026-05-14 20:25 EST

HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results

ANABAnaptysBio, Inc.2026-05-12 20:15 EST

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

MREOMereo BioPharma2026-05-12 11:30 EST

Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates

IMVTImmunovant2026-05-11 20:05 EST

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

GPCRStructure Therapeutics2026-05-07 20:06 EST

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

ALECAlector2026-05-07 20:05 EST

Alector Reports First Quarter 2026 Financial Results and Provides Business Update

ZURAZura Bio2026-05-07 11:30 EST

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

View all latest news

Exagen

Exagen is a diagnostics company focused on autoimmune and rheumatology testing. Its business is built around helping clinicians make better decisions through advanced blood-based diagnostics.

Recent company news

XGNExagen2026-06-01 13:00 EST

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

XGNExagen2026-05-11 12:00 EST

Exagen Inc. Reports First Quarter 2026 Results

XGNExagen2026-04-27 13:00 EST

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

XGNExagen2026-03-10 12:00 EST

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

XGNExagen2026-03-03 14:00 EST

Exagen Inc. to Participate in Upcoming Investor Conferences

Stock data

Close
4.45 USD
Market cap
116.45M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States